(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Blueprint Medicines Corporation
The Methodist Hospital Research Institute
VA Office of Research and Development